Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Britannia Life Sciences Inc Com C.RLSC

RISE Life Science Corp is engaged in developing and evolving medical and adult hemp-based formulations to create general use of health and well-being products for the emerging consumer category. It derives key revenue from the United States.


CSE:RLSC - Post by User

Comment by GianniM1on Jun 20, 2015 4:43pm
135 Views
Post# 23852265

RE:Amway, Chinese FDA, other thoughts...

RE:Amway, Chinese FDA, other thoughts...Thanks CasusFortuitus.

Just wanted to add to the group:

I've watched these interviews a few times when they were first published and want to highlight that both Amway AND the Chinese (Cachet Pharmaceuticals) bothreached out to Miraculins.

Not the other way around.

Meaning, they see value in the product(s) and IPs. It will be a matter of time before Miraculins will be looking and implementing ways to extract this value. The "looking" part is already underway from all the updates and news releases thus far, and now we are waiting on the "implemetation".

So for those that think that their product is not capable of selling or Miraculins is like the company of the past, need to rethink this through again.

You simply cannot compare the company of today to the company of the past ( when it was in Veralights hands and the fact that it not do anything with them).

Look at the objectives from today and the objectives/direction of the past (if there was anything).

Different management, different objectives, different marketing/approach, etc....

Can the SP go any lower? maybe with a few games (but not holding my breath, nor do I care since I am happy with what i got in at)...

....but if you think about it, it is at the lowest point since inception, and not until NOW they have formalized their milestones/objectives and have already put those milestones in action....

.....so what direction do you think the SP will eventually go ?

The big question is when.... not can they.




CasusFortuitus wrote: I watched the Investor Intel interview and a couple more that were listed in the YouTube suggestions. Below each link are some take-aways and other thoughts.

Published on Jun 12, 2015
https://www.youtube.com/watch?v=zOCQKDx3dGM&feature=youtu.be

1. USFDA De Novo process going forward. "Hoping to begin more specific plans for a study in the Fall." Now does this mean that the plans for the study will be started in the Fall or that the study itself will begin in the Fall? When exactly is "the Fall?" Sept? Oct? Nov? Dec?

2. Amway reached out to Miraculins regarding possibility of replacing their own less advanced, non-portable skin screening device by using Miraculins IP to build a novel product. The two companies conducted a skin screening study and Amway is presenting the "promising data" at Dermatology conferences. They are not in discussions for Amway to sell the Scout, but possibly collaborating to produce a new, non-medical device product utilizing same IP on which Scout is based. I'm guessing this will probably be some sort of small, handheld "home health" type skin screening device.

3. Company is at "product testing phase" in CFDA process. Major distribution deal (up to $90 Million!) for Scout hinges on CFDA approval. Hospitals across China want to set up "banks and banks" of Scout screening devices to screen patients when they walk in the door.

Published on Feb 3, 2015
https://www.youtube.com/watch?v=q6XVBINVTpc

Short, general corporate promo piece. Nothing groundbreaking.

Published on Jan 27, 2015
https://www.youtube.com/watch?v=uzauDJ00RQM

1. $15 Million up-front order for Scout devices upon CFDA approval, anticipated to be in "12 to 16 months." Yikes. Additional $15 Million "exclusivity" payments in years 2-5.

2. Other 2014 milestones included "discussions" with USFDA regarding De Novo submission of Scout for regulatory Class II medical device approval. Of course we now know that the FDA responded favorably and Miraculins is moving forward with the De Novo process. Yay!

3. Miraculins transitioned in-house manufacturing to a mid-sized US-based device manufacturer Avo Photonics in Philadelphia, PA.

4. Major UC/Canada markets for Scout include:
  • General Practitioner / Family practice doctor's office (slow, difficult to break into, working on getting insurance reimbursement classification.)
  • Retail pharmacy / grocery store pharmacy (each customer w/ Type II Diabetes represents ~$3000/yr in medication and supplies that could be bought from the store/pharmacy.)
  • Workplace screening for employees, corporate wellness programs, Miraculins initiating 2015 pilot programs with "large Canadian employers."



Bullboard Posts